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CorrespondenceResponse to Drs. Djouadi and
BastinDear Editor,
We thank Drs. Djouadi and Bastin for
their comments and are pleased to share
with them the view that pharmacological
activation of mitochondrial biogenesis is
exploitable to correct oxidative phosphor-
ylation (OXPHOS) defects (Viscomi et al.,
2011). In 2008, Wenz et al. reported that,
similar to muscle-restricted transgenic
overexpression of PGC-1a, treatment
with the pan-PPAR activator bezafibrate
(bzf), a widely used hypolipidemic drug,
increased the expression of OXPHOS-
related genes and enzymatic activities in
muscle-specific COX10KO mice, resulting
in clinical improvement and increased
life span. The proposed mechanism was
based on increased expression of
PGC-1a (Wenz et al., 2008). This remark-
able observation prompted us to try bzf in
additional COX-defective mouse models.
In order to avoid methodological criti-
cisms, we adopted the very same experi-
mental procedure followed byWenz et al.,
including drug dosage (0.5% bzf in chow
diet). We agreewith Drs. Djouadi andBas-
tin that this dosage is proportionally much
higher than that recommended for
patients. However, we wish to emphasize
that (1) this was the same dosage used
by Wenz et al., (2) this dosage is standard
for experiments in mice, and (3) lower
dosage (10 mg/kg/day), comparable to
that used in humans, is ineffective
to activate PPAR-a in mice, in contrast
to much higher dosages (100 mg/kg/
day) (Nakajima et al., 2009). Accordingly,
our treated animals showed increased
expression of PPAR-a and fatty acidoxidation (FAO)-related genes, demon-
strating that the treatment was indeed
effective on the main known target
pathway of bzf. Conversely, bzf com-
pletely failed to stimulate the expression
of OXPHOS-related genes in both muscle
and liver of our animals, either controls or
diseasemodels; themtDNA content actu-
ally decreased in liver and remained
unchanged in muscle, and the activity of
RC complexes was unchanged or
reduced in both tissues. Induction of
PGC-1a and OXPHOS by the PPAR
system is a rather controversial issue
(Kleiner et al., 2009); in our own experi-
ments we failed to observe significant
changes in the expression of PGC-1a in
muscle under bzf treatment. The point
raised by Drs. Djouadi and Bastin on bzf
hepatotoxicity in rodents is concordant
with liver enlargement and elevation of
serum transaminases found in our bzf-
treated animals. However, we think that
this observation is marginal and in fact
irrelevant to the scope of our study that
aimed, as far as bzf is concerned, at veri-
fying the results of Wenz et al. The fact
that bzf is myotoxic in our ACTA-
COX15KO animals is also eccentric to the
main issues of our work but could obvi-
ously not be ignored.
Next, we showed that activation of
PGC-1a via phosphorylation, using the
AMP kinase agonist AICAR, led to
increased expression of both FAO- and
OXPHOS-associated genes, increased
mtDNA content, and increased respira-
tory chain complex activities in skeletal
muscle of control and COX-defectiveCell Metabolism 14,mice. This result demonstrates that phar-
macological induction of mitochondrial
biogenesis via PGC-1a activation is
feasible and can be beneficial in mito-
chondrial disease.
The final point raised by Drs. Djouadi
and Bastin stems from their own
experimental observation that treatment
with bzf induces OXPHOS-related gene
expression and enzyme activities in
skeletal muscle of six CPT-II-deficient
patients. Albeit preliminary, these data
suggest different responses of OXPHOS
gene expression to bzf in humans versus
rodents. Futurework is warranted to verify
and expand this encouraging result, eluci-
date the mechanisms of species speci-
ficity, and hopefully validate safe usability
and effectiveness of this drug for treating
mitochondrial disease patients.
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